Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human epidermal growth factor receptor 2 ( HER2 ) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapy

2 Sept 2020

Abstract excerpt

Objectives To evaluate human epidermal growth factor receptor 2 (HER2) protein overexpression by immunohistochemistry (IHC) and gene amplification by fluorescent in situ hybridisation (FISH) in urothelial non-muscle-invasive bladder carcinoma (NMIBC), as HER2 is a potential therapeutic target in muscle-invasive bladder carcinoma (MIBC) and HER2 expression and gene amplification in low/high-grade and pTa/pT1 NMIBC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to HER2/EGFR in Cancer Research
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33312739
DOI: 10.1080/2090598x.2020.1814183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human epidermal growth factor receptor 2 ( HER2 ) gene amplification in non-muscle invasive urothelial bladder cancers: Identification of patients for targeted therapyPMID 33312739Read ↗

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.Semantic proximity Read ↗

The Role of Immunohistochemistry as a Surrogate Marker in Molecular Subtyping and Classification of Bladder CancerSemantic proximity Read ↗

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.Semantic proximity Read ↗

MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle‐invasive bladder cancerSemantic proximity Read ↗

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Semantic proximity Read ↗

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.Semantic proximity Read ↗

Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16Semantic proximity Read ↗

Effect of HER2 and Fascin expression on muscle-invasive bladder cancers: Classification by basaloid and luminal phenotypes.Semantic proximity Read ↗

Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.Semantic proximity Read ↗

HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contextsSemantic proximity Read ↗

Morphological and molecular characteristics of HER2 amplified urothelial bladder cancerSemantic proximity Read ↗

TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.